N@N

ALEXION PHARMACEUTICALS INC (NASDAQ:ALXN), Up By 11.43% ($9.52) From $83.280 After BUYINS.NET Report Predicted Strength Before

^{Published on 2012-03-22 05:40:46 - WOPRAI}
 

March 22, 2012 / M2 PRESSWIRE / BUYINS.NET, www.buyins.net , a provider of unique trading technologies, released a report on Wednesday, March 7th 2012 stating that ALEXION PHARMACEUTICALS INC (NASDAQ:ALXN) was expected to be Up Before its earnings release. Click here to view the BUYINS.NET report: http://www.buyins.net/releases/?sym=alxn&id=251278

At the time this story was written, ALEXION PHARMACEUTICALS INC (NASDAQ:ALXN) is Up By 11.43% ($9.52) From $83.280 since the BUYINS.NET report was released.

The movement of stock prices in the days and weeks leading to and following earnings announcements may follow a predictable pattern. Most companies stock price histories show random or unpredictable movements around earnings dates. But some seem to repeat the same pattern quarter after quarter, year after year. The specific technology used to make these predictions is available for a low monthly fee at http://www.squeezetrigger.com/services/strat/mh.php

ALEXION PHARMACEUTICALS INC (NASDAQ:ALXN) - Alexion Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of biologic therapeutic products in the United States, Europe, Latin America, Japan, and the Asia Pacific. It focuses on products for severe and life-threatening disease states, including hematologic, kidney, and neurologic diseases; transplant rejection; cancer; and autoimmune disorders. The company markets Soliris (eculizumab) for the treatment of patients with paroxysmal nocturnal hemoglobinuria, a blood disorder. It also conducts various Phase II clinical trials on Soliris for the treatment of atypical hemolytic uremic syndrome, MPGN II dense deposit disease, presensitized renal transplant, myasthenia gravis, neuromyelitis optica, multifocal motor neuropathy, and dry age-related macular degeneration. In addition, the company conducts preclinical studies on Soliris for the treatment of presensitized cardiac transplant, cold agglutinin disease, and catastrophic antiphospholipid syndrome. Further, its clinical programs include Samalizumab, which is in Phase I/II clinical trials for the treatment of chronic lymphocytic leukemia and multiple myeloma. Alexion Pharmaceuticals serves specialty distributors and specialty pharmacies, which supply physician office clinics, hospital outpatient clinics, infusion clinics, or home health care providers; government agencies; and hospitals, hospital buying groups, pharmacies, other healthcare providers, and distributors. The company was founded in 1992 and is headquartered in Cheshire, Connecticut.

About BUYINS.NET

BUYINS.NET, www.buyins.net , monitors trading in all US stocks in real time and maintains massive databases of short sale and naked short sale time and sales data, short squeeze SqueezeTrigger prices, market-maker price movements, shareholder data, statistical data on earnings, sector correlation, seasonality, hedge fund trading strategies, comparable valuations. Reports include:

REGULATORY & COMPLIANCE NEWS

Friction Factor -- market-maker surveillance system tracking market makers in all stocks to determine Price Friction and compliance with new "Fair Market-Making Requirements".

RegSHO Naked Shorts -- tracks EVERY failure to deliver in all US stocks and all Threshold Security Lists daily for which stocks have naked short positions.

INVESTMENTS & TRADING

SqueezeTrigger -- 28 billion cell database tracks EVERY short sale (not just total short interest) in all US stocks and calculates volume weighted price that a short squeeze will begin in each stock.

Earnings Edge -- predicts probability, price move and length of move before and after all US stock earnings reports.

Seasonality -- predicts probability, price move and length of move based on exact time of year for all US stocks.

Group Trader -- tracks sector rotation and stock correlation to its sector and predicts future moves in ALL sectors and industry groups.

Pattern Scan -- automates tracking of every technical pattern and predicts next move in stocks.

GATS -- tracks and quantifies known trading strategies.

DISCLAIMER:

BUYINS.NET is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. ALEXION PHARMACEUTICALS INC (NASDAQ:ALXN) has not approved the statements made in this release. Please read our report and visit our web site, http://www.buyins.net, for complete risks and disclosures.

Contact: BUYINS.NET Thomas Ronk 800-715-9999 tom@buyins.net http://www.buyins.net